Literature DB >> 27185080

Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease.

Yoosoo Chang1,2,3, Hyun-Suk Jung1, Juhee Cho1,3,4, Yiyi Zhang4,5,6, Kyung Eun Yun1, Mariana Lazo4,5,6, Roberto Pastor-Barriuso7, Jiin Ahn1, Chan-Won Kim1, Sanjay Rampal4,6,8, Miguel Cainzos-Achirica4,6,9, Di Zhao4,5,6, Eun Cheol Chung10, Hocheol Shin11, Eliseo Guallar4,5,6, Seungho Ryu1,2,3.   

Abstract

OBJECTIVES: The risk of nonalcoholic fatty liver disease (NAFLD) among obese individuals without obesity-related metabolic abnormalities, a condition referred to as metabolically healthy obese (MHO), is largely unexplored. Therefore, we examined the association between body mass index (BMI) categories and the development of NAFLD in a large cohort of metabolically healthy men and women.
METHODS: A cohort study was conducted in 77,425 men and women free of NAFLD and metabolic abnormalities at baseline, who were followed-up annually or biennially for an average of 4.5 years. Being metabolically healthy was defined as not having any metabolic syndrome component and having a homeostasis model assessment of insulin resistance <2.5. The presence of fatty liver was determined using ultrasound.
RESULTS: During 348,193.5 person-years of follow-up, 10,340 participants developed NAFLD (incidence rate, 29.7 per 1,000 person-years). The multivariable adjusted hazard ratios (95% confidence intervals) for incident NAFLD comparing overweight and obese with normal-weight participants were 2.15 (2.06-2.26) and 3.55 (3.37-3.74), respectively. In detailed dose-response analyses, increasing baseline BMI showed a strong and approximately linear relationship with the incidence of NAFLD, with no threshold at no risk. This association was present in both men and women, although it was stronger in women (P for interaction <0.001), and it was evident in all clinically relevant subgroups evaluated, including participants with low inflammation status.
CONCLUSIONS: In a large cohort of strictly defined metabolically healthy men and women, overweight and obesity were strongly and progressively associated with an increased incidence of NAFLD, suggesting that the obese phenotype per se, regardless of metabolic abnormalities, can increase the risk of NAFLD.

Entities:  

Mesh:

Year:  2016        PMID: 27185080     DOI: 10.1038/ajg.2016.178

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  43 in total

1.  Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

2.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

3.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

4.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.

Authors:  Ruben Hernaez; Mariana Lazo; Susanne Bonekamp; Ihab Kamel; Frederick L Brancati; Eliseo Guallar; Jeanne M Clark
Journal:  Hepatology       Date:  2011-09-02       Impact factor: 17.425

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 6.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

7.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

8.  Thyroid hormone levels and incident chronic kidney disease in euthyroid individuals: the Kangbuk Samsung Health Study.

Authors:  Yiyi Zhang; Yoosoo Chang; Seungho Ryu; Juhee Cho; Won-Young Lee; Eun-Jung Rhee; Min-Jung Kwon; Roberto Pastor-Barriuso; Sanjay Rampal; Won Kon Han; Hocheol Shin; Eliseo Guallar
Journal:  Int J Epidemiol       Date:  2014-10       Impact factor: 7.196

Review 9.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

10.  Need for a paradigm shift in adult overweight and obesity management - an EASO position statement on a pressing public health, clinical and scientific challenge in Europe.

Authors:  Gema Frühbeck; Hermann Toplak; Euan Woodward; Jason C G Halford; Volkan Yumuk
Journal:  Obes Facts       Date:  2014-12-05       Impact factor: 3.942

View more
  62 in total

1.  Diabetes mellitus is associated with an increased risk of gastric cancer: a cohort study.

Authors:  Hyo-Joon Yang; Danbee Kang; Yoosoo Chang; Jiin Ahn; Seungho Ryu; Juhee Cho; Eliseo Guallar; Chong Il Sohn
Journal:  Gastric Cancer       Date:  2019-12-18       Impact factor: 7.370

Review 2.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

3.  Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis.

Authors:  Hyo-Joon Yang; Yoosoo Chang; Soo-Kyung Park; Yoon Suk Jung; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Seungho Ryu; Chong Il Sohn
Journal:  Dig Dis Sci       Date:  2017-10-23       Impact factor: 3.199

4.  PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells.

Authors:  Wenfeng Zhang; Yan Liu; Mingbing Wu; Xiwen Zhu; Tao Wang; Kun He; Peizhi Li; Xiaoling Wu
Journal:  J Physiol Biochem       Date:  2017-09-13       Impact factor: 4.158

5.  A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study.

Authors:  Michelle T Long; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Jiantao Ma; Rohit Loomba; Raymond T Chung; Emelia J Benjamin
Journal:  Liver Int       Date:  2018-03-12       Impact factor: 5.828

6.  Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus.

Authors:  Mojtaba Malek; Mohammad E Khamseh; Haleh Chehrehgosha; Sohrab Nobarani; Fariba Alaei-Shahmiri
Journal:  Endocrine       Date:  2021-08-05       Impact factor: 3.633

7.  Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes.

Authors:  Wenshuai Li; Xiangzhu Zhu; Yiqing Song; Lei Fan; Lijun Wu; Edmond K Kabagambe; Lifang Hou; Martha J Shrubsole; Jie Liu; Qi Dai
Journal:  Public Health Nutr       Date:  2018-04-02       Impact factor: 4.022

8.  Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.

Authors:  Yong Tang; Guojun Cao; Xiaobo Min; Tao Wang; Shiran Sun; Xiaolong Du; Weikang Zhang
Journal:  J Physiol Biochem       Date:  2018-07-17       Impact factor: 4.158

9.  Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? evidence from the multi-ethnic study of atherosclerosis (MESA).

Authors:  Luis A Rodriguez; Alka M Kanaya; Stephen C Shiboski; Alicia Fernandez; David Herrington; Jingzhong Ding; Patrick T Bradshaw
Journal:  Ann Epidemiol       Date:  2021-07-19       Impact factor: 3.797

10.  Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy.

Authors:  Nam Hee Kim; Yoon Suk Jung; Jung Ho Park; Dong Il Park; Chong Il Sohn
Journal:  Korean J Intern Med       Date:  2020-07-07       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.